quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:32:44·37d
INSIDERFiling
Tarsus Pharmaceuticals Inc. logo

Chief Commercial Officer Mottiwala Aziz converted options into 26,482 shares, increasing direct ownership by 55% to 74,536 units (SEC Form 4)

TARS· Tarsus Pharmaceuticals Inc.
Health Care
Original source

Companies

  • TARS
    Tarsus Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Apr 24UpdateOppenheimer$98.00
  • Dec 9UpdateBarclays$100.00
  • Nov 20UpdateMizuho$100.00
  • Jun 2UpdateOppenheimer$75.00
  • May 27UpdateH.C. Wainwright$72.00
  • Nov 20UpdateGoldman$19.00

Related

  • ANALYST2h
    Oppenheimer resumed coverage on Tarsus Pharmaceuticals with a new price target
  • PR24d
    Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.
  • INSIDER30d
    SEC Form 4 filed by Neervannan Seshadri
  • PR32d
    TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
  • INSIDER35d
    SEC Form 4 filed by Whitfield Dianne C.
  • INSIDER35d
    SEC Form 4 filed by Wahl Bryan
  • INSIDER35d
    SEC Form 4 filed by Neervannan Seshadri
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022